tsDMARDohjelma
tsDMARDohjelma is a term used to describe a structured program for implementing targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) within clinical practice. tsDMARDs, such as JAK inhibitors, are used to treat inflammatory autoimmune conditions and are distinguished from conventional synthetic DMARDs (csDMARDs) and biological DMARDs. A tsDMARDohjelma aims to standardize patient selection, dosing, monitoring, and safety oversight to improve treatment outcomes and ensure consistent care.
The program typically encompasses guidelines for when tsDMARDs should be considered, including disease type, prior therapies,
Safety considerations are central to a tsDMARDohjelma, given risks such as infections, thromboembolism, and alterations in